Microbot Medical Inc. (MBOT) Fair Value 2026

MBOT · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.9 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (34/100)

Quick Summary — As of 2026-08-28, Microbot Medical Inc. (MBOT) trades at $1.48. QOC: 4.9/10. Value Trap Risk: 34/100 (LOW). 1/13 models active.

Key Facts

Ticker
MBOT
Price
$1.48
Quality Score
4.9/10
Value Trap Risk
34/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.9/10 signals weak fundamentals

What Fair Value Does Each Model Give MBOT?

1 Intrinsic Value Models vs. Current Price ($1.48)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $0.80 -46.0%

All Models Active

All 1 models are displayed above.

What Is Microbot Medical Inc. (MBOT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Microbot Medical Inc.'s intrinsic value is estimated at $0.80. Trading at its current price of $1.48, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -46.0%.

What Do the Models Say About MBOT?

1 of 13 models are currently active for MBOT. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does MBOT Rank in Medical Devices?

Among 159 Medical Devices stocks, MBOT ranks #128 by Quality of Company score. CirclFi's QOC score of 4.9/10 evaluates 32 fundamental signals. A score of 4.9 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

The Medical Devices sector introduces analytical considerations specific to pharmaceutical industry businesses. For Microbot Medical Inc., metrics like R&D productivity ratio provide important context that general-purpose valuation models may underweight.

Is MBOT a Value Trap?

CirclFi's Value Trap algorithm assigns MBOT a score of 34/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Microbot Medical Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Microbot Medical Inc. scores 4.9 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every MBOT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across MBOT's 1 active models, average confidence is 53%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Microbot Medical Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

HSCSHeartSciences Inc.QOC 4.9FEEDENvue Medical, Inc.QOC 4.8TNONTenon Medical, Inc.QOC 5.0TRIBTrinity Biotech plcQOC 4.8VTAKCatheter Precision, Inc.QOC 5.0ALURAllurion Technologies Inc.QOC 4.8SYKStryker CorporationQOC 9.0IRTCiRhythm Holdings, Inc.QOC 7.1ENOVEnovis CorporationQOC 6.1IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: HSCS · FEED · TNON · TRIB · VTAK · ALUR · SYK · IRTC · ENOV · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to MBOT?

7 companies across all industries closest to MBOT’s Quality of Company score of 4.9/10.

WNDWSolarWindow Technologies, Inc.QOC 4.9GDCGD Culture Group LimitedQOC 4.9NEXMNexMetals Mining Corp.QOC 4.9BICXBioCorRx Inc.QOC 4.9LTBRLightbridge CorporationQOC 4.9ISPCiSpecimen Inc.QOC 4.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: WNDW · GDC · NEXM · BICX · LTBR · ISPC · NVDA

Where Does MBOT Sit in CirclFi's Medical Devices Rankings?

MBOT is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Microbot Medical Inc.’s Valuation?

What is Microbot Medical Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Microbot Medical Inc. (MBOT). The Quality of Company score is 4.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is MBOT overvalued or undervalued right now?

At $1.48, 0 of 1 active models suggest MBOT may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Microbot Medical Inc.'s business model in Medical Devices.

What does a Quality of Company score of 4.9 mean for MBOT?

Microbot Medical Inc.'s QOC of 4.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on MBOT?

CirclFi analyzes MBOT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is MBOT a value trap in 2026?

Microbot Medical Inc.'s Value Trap score is 34/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Microbot Medical Inc. (MBOT) a Quality of Company score of 4.9/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/MBOT/ · Methodology
Primary sources for this MBOT valuation
  • Financial statements: Microbot Medical Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000883975) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for MBOT as of ; valuations recomputed .